Distribution of human papillomavirus types in Shenzhen women

Acta Academiae Medicinae Sinicae

Volumn 28, Issue 6, 2006, Pages 832-836

  Shi, Ju Fang ^a   Wu, Rui Fang ^b   Liu, Zhi Hua ^c   Zhou, Qing Zhi ^d   Li, Ni ^e   Wu Lan, Na ^b   Li, Qing ^c   Wang, Qian ^d   Liu, Bin ^e   Li, Rui Zhen ^b   Qiao, You Lin ^e  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^c Shenzhen Maternal and Child's Healthcare Hospital   (China)

^d Population and Family Planning Bureau of Nanshan District   (China)

^e CANCER HOSPITAL   (China)

Author keywords

Cervical cancer; Distribution; Human papillomavirus; Type

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER SCREENING; CHINA; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; QUESTIONNAIRE; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS TYPING; WART VIRUS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHINA; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DISEASES;

EID: 33846420175     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. The International Agency for Research on Cancer. GLOBOCAN 2002 database: summary table by cancer. http://www.dep.iarc.fr.
2. Chinese source. 2002, 24(1):50-54.
3. Chinese source. 2004. 212-240.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1):12-19.
5. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 2004, 364 (9447): 1757-1765.
6. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis, 2003, 3(8):469-475.
7. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 2005, 6(5):271-278.
8. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005, 6(4):204.
9. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 1995, 87(11):796-802.
10. Chinese source. 2005, 28(5):495-497.
11. Chinese source. 2006, 86(5):307-311.
12. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 2005, 366 (9490):991-998.
13. Chinese source. 1996, 10(1):50-55.
14. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer, 1993, 53(6):919-923.
15. Chinese source. 2003, 25(4):381-385.